【国药现代:阿奇霉素干混悬剂通过仿制药一致性评价】国药现代公告,公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售,但业绩影响存在不确定性。

金融界
26 Jun
国药现代公告,公司阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂2024年全国公立医疗机构及城市药店销售额为14.75亿元。目前通过一致性评价的企业包括石药集团欧意药业有限公司、宜昌东阳光长江药业股份有限公司、苏州东瑞制药有限公司、海南普利制药股份有限公司等。公司累计研发投入约1737.25万元。本次通过一致性评价有利于产品市场拓展和销售,但业绩影响存在不确定性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10